Degnan Chris 4

What Happened
Chris Degnan, Chief Financial Officer of UroGen Pharma Ltd. (URGN), received a grant of 32,609 restricted stock units (RSUs) reported on Form 4 for the 2026-01-31 transaction date. The award is reported at $0.00 per unit (no cash paid). Each RSU is a contingent right to receive one ordinary share upon vesting; the filing does not state an immediate cash value.

Key Details

• Transaction date: 2026-01-31; Form 4 filed: 2026-02-03.
• Transaction type/code: Award/Grant (Code A); amount: 32,609 RSUs; reported price: $0.00.
• Vesting schedule (footnote): 1/3 of the RSUs vest on each of Jan 31, 2027; Jan 31, 2028; Jan 31, 2029.
• Footnotes: F1 — each RSU = right to one ordinary share; F2 — vesting schedule as above.
• Shares owned after transaction: Not specified in the provided filing summary.
• Filing timeliness: No late‑filing indicator provided in the data.

Context
RSU grants are compensation/retention awards and differ from open‑market purchases or sales; they do not reflect an immediate cash investment by the insider. RSUs convert into actual shares only as they vest. To estimate the grant’s market value, multiply 32,609 by UroGen’s share price around the grant date (price not included in the filing).